Transcript Document

TREATMENT DATA INDICATORS IN
THE UNODC DATA COLLECTION
SYSTEM
IMPORTANCE OF TDI EXPERIENCES IN EUROPE
FOR UNODC
• EU WORK ON HARMONIZATION OF DATA
COLLECTION SYSTEMS PROVIDES IMPORTANT
GUIDANCE ON HOW TO WORK AT GLOBAL LEVEL.
• TREATMENT DATA ARE IN MANY COUNTRIES THE
ONLY DATA COLLECTED AND IMPROVING THEM IS
AN IMPORTANT ELEMENT OF BUILDING NATIONAL
INFORMATION SYSTEM.
REPORTING ON DRUG DEMAND REDUCTION
• Developing an information set to measure achievement
in respect of the targets detailed in the Political
Declaration and the Demand Reduction Declaration
• Goals for 2003: establishment of legal measures and
programmes (reviewed during the Ministerial Segment
of the Commission on Narcotic Drugs in April 2003)
• Goals for 2008: to significantly reduce demand for illicit
drugs.
ACTION PLAN ON DEMAND REDUCTION
Under the Action Plan UNODC has been given 3 specific
tasks:
–To facilitate sharing of good practice strategies and
programmes
–To provide assistance in developing DDR strategies in
line with the Guiding principles of drug demand reduction
–To provide assistance for the establishment of national
data collection systems.
GUIDING PRINCIPLES OF UNDCP DATA
COLLECTION STRATEGY
• Sensitivity to different information resources
• Based on agreed standards of good practice
• Comparability with other information sets
BIENNIAL REPORTS QUESTIONNAIRE (BRQ)
on Demand Reduction Activities
• Mandated follow-up instrument of the UNGASS
process
• To enable Member States to report on the progress
achieved in meeting the UNGASS objectives for
2003 and 2008
• To monitor structures, methods of working, target
population, extent and coverage of programmes,
difficulties encountered
BIENNIAL REPORTS QUESTIONNAIRE (BRQ)
on Demand Reduction Activities
• Extent of coverage (low /medium or high) and
programme execution (gender sensitive and
evaluated in the areas of treatment and
rehabilitation:
• detoxification
• substitution treatment (therapy) excluding shortterm detoxification
• non-pharmacological treatment
• social reintegration
ANNUAL REPORTS QUESTIONNAIRE (ARQ)
on Drug Abuse
• To review the progress made in meeting the
challenges set out in the Political Declaration
adopted by the General Assembly
• To monitor and increase global understanding of
the extent and nature of drug abuse
ANNUAL REPORTS QUESTIONNAIRE (ARQ)
Quantitative estimates and expert opinions on:
• prevalence of drug abuse among general and youth population
• prevalence of drug abuse among the school (youth) population
• injecting drug abuse
• severe drug abuse
• new developments in prevalence and patterns of drug abuse
• drug-related morbidity (HIV, HBV, HCV)
• Drug-related mortality
• drug treatment
• data collection capacity
ANNUAL REPORTS QUESTIONNAIRE (ARQ)
• Annually distributed to all Member States
• Annual Reports Questionnaire, 2001:103
submissions, response rate 54 %
• Electronic completion and submission made
possible
ANNUAL REPORTS QUESTIONNAIRE (ARQ)
TREATMENT DEMAND
• Summary Expert Opinions
– Have people received treatment yes/no by drugs
– Ranking drugs as primary cause of receiving treatment
– Trends in the past in number of people receiving treatment
(large/some increase/decrease or stable)
ANNUAL REPORTS QUESTIONNAIRE (ARQ)
TREATMENT DEMAND
• Quantitative Estimates
–
–
–
–
–
–
Estimated number of people receiving treatment
Percentage of people receiving treatment for first time ever
Percentage of females
Mean age
Percentage of drug injectors
Definition of “people treated for drug problems”
No. of people receiving treatment for cannabis type in Asia
Tajikistan
1
217
Saudi Arabia
Asia
Philippines
1698
Mongolia
2
Macau
5
Korea (Republic of)
15
Indonesia
71
0
200
400
600
800
1000
1200 1400
1600 1800
Europe
No. of people receiving treatment for cannabis
type in Europe
United Kingdom
Sw eden
Slov akia
Poland
Netherlands
Lux embourg
Liechtenstein
Latv ia
Italy
Ireland
Iceland
Hungary
Greece
France
Croatia
3489
336
184
256
3443
65
8
50
12452
728
600
2301
239
3030
1295
0
2000
4000
6000
8000 10000 12000 14000
No. of people receiving treatment for cannabis type in
the Americas
88
Trinidad Tobago
116
Americas
Saint Vincent and the Grenadines
20
Haiti
7
Grenada
11
Dominican Republic
214
Argentina
0
50
100
150
200
250
P e rc e nt a ge o f pe o ple re c e iv ing t re a t m e nt f o r t he f irs t e v e r t im e a m o ng
pe o ple in t re a m e nt f o r c a nna bis t ype
4
Grenada
8
Hungary
9
Dominican Republic
M ongolia
14
M auritius
14
19
Saint Vincent and the Grenadines
23
Haiti
40
Liechtenstein
56
France
61
Saudi Arabia
66
Ireland
69
Netherlands
71
Slovakia
80
Latvia
81
Greece
84
Indonesia
96
Seychelles
0
10
20
30
40
50
60
70
80
90
100
Estimated mean age of people in treatment for
cannabis type
Seychelles
Dominican Republic
Saint Kitts and Nevis
Saint Vincent and the Grenadines
Korea (Republic of)
Saudi Arabia
Croatia
France
Greece
Ireland
Liechtenstein
Netherlands
Slovakia
Turkey
23
25
25
29
31
28
16
26
21
22
22
28
20
28
Estimated percentage of females among people in
treatment for cannabis type
Mauritius
Seychelles
Saint Vincent and the Grenadines
Trinidad Tobago
Indonesia
Macau
Croatia
France
Greece
Hungary
Ireland
Latvia
Netherlands
Poland
Slovakia
Turkey
United Kingdom
2
8
5
8
4
1
4
18
11
4
18
20
19
2
18
8
18
Global Assessment Programme on Drug Abuse
(GAP)
The Global Assessment Programme (GAP) on Drug Abuse
has facilitated an understanding of and improved
information on the global drug situation.
Lisbon consensus January 2000 agreement on a set of
core Indicators
•Prevalence and incidende general population
•Prevalence and incidence youth population
•High-risk drug abuse
•Drug-related morbidity
•Drug-related mortality
Global Assessment Programme on Drug Abuse
(GAP)
At the national level the GAP has:
•conducted information, need and resource analyses to
produce strategic action plans
•Supported the establishment of data collection focal
points and expert networks
•Provided training and resources to meet key information
needs
Global Assessment Programme (GAP)
Through its regional activities:
• GAP has supported regional information systems
• Encouraged networking among countries
• Provided opportunities for training
At the global level:
• Dissemination of methodological developments and
best practices (toolkit with modules on information
systems, school surveys, estimation techniques, data
management and analysis)
• Improved reporting standards
• Increased the quality and coverage of the global
information base
Global Assessment Programme (GAP) next steps
• Technical support to regional sub-programmes and
national epidemiological units
• Further development and harmonization of indicators
and data collection methodologies
• Regional network development and exchange of
information, experience and survey results among
national epidemiological units in the region;
• Promotion of the use of existing training packages
(“methodological toolkit”) developed under the GAP
and provision of technical assistance for regional
training;
Global Assessment Programme (GAP) next steps
• Development of training packages and
organization of regional training programmes on:
•
•
•
•
ARQ data management and interpretation to support policy planning;
Qualitative research and focused assessment studies;
Ethical issues and principles for drug abuse epidemiology;
Treatment reporting (possible cooperation with EMCDDA and other
agencies);
• Monitoring of injecting drug abuse and associated HIV-related factors
• Technical assistance to national focal points in
collection of national and regional data on drug
abuse